Pharmaceutical Business review

FDA approves Regeneron’s Livsayis for generalised myasthenia gravis

Regeneron manages Livsayis’ manufacturing and commercialisation under a global agreement with Alnylam. Credit: lev radin/Shutterstock.com.

Administered subcutaneously four times annually, the therapy is a small interfering RNA designed to decrease circulating complement component factor 5 protein levels and curb terminal complement activation.

The regulatory clearance was based on findings from the ongoing randomised, double-blind, placebo-controlled Phase III NIMBLE study (NCT05070858) evaluating the treatment in individuals maintaining discretionary background immunosuppressants.

At 24 weeks, the recipients recorded a 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living scores versus 2.2 points for placebo, demonstrating a statistically significant 2.3-point difference.

The patients also displayed earlier functional gains within two weeks, with 76.6% achieving at least a 3-point improvement at week 24 compared to 44.1% on placebo.

In the clinician-administered Quantitative Myasthenia Gravis assessment, the medicine produced a 4.2-point improvement compared with 1.5 points for placebo, yielding an adjusted gain of 2.8 points.

A 5-point or greater improvement occurred in 48.4% of treated patients against 19.0% on placebo, with symptom control continuing throughout the 24-week period without diminished efficacy.

Adverse reactions affecting at least 5% of patients included injection site reactions, urinary tract infections, and viral infections.

Regeneron board co-chair, president and chief scientific officer George Yancopoulos said: “Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalised myasthenia gravis who need effective disease control without a heavy treatment burden.

“As Regeneron’s first approved siRNA therapy, this approval marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases.”

Regeneron manages the therapy’s manufacturing, commercialisation, and clinical progression under a global agreement with Alnylam, while facilitating patient access and benefit verification via its myRARE programme.

Health authorities in the European Union are currently reviewing the treatment, with a decision expected during late 2027, alongside planned submissions in additional territories, including Japan.

Last month, Regeneron agreed to a nearly $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government through 2031.

Exit mobile version